Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG)

Authors :: Sven Mahner
F Marmé
Florence Joly
Jean-Emmanuel Kurtz
Jörn Rau
Ahmed El-Balat
P. Harter
Alexander Hein
Klaus Baumann
Andrew Dean
Catherine Shannon
Jalid Sehouli
Ulrich Canzler
R.M. Glasspool
Daniel Reimer
Jacobus Pfisterer
N de Gregorio
Lars Hanker
Thierry Petit
Barbara Schmalfeldt
Source :: Annals of Oncology. 29:viii332-viii333
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Full Text Access

Tools